{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:27:46Z","timestamp":1788200866302,"version":"build-2803163510"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["18170902"],"award-info":[{"award-number":["18170902"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Regarding primary and secondary cervical cancer prevention, the World Health Organization proposed the cervical cancer elimination strategy that requires countries to achieve 90% uptake of human papillomavirus (HPV) vaccines and 70% screening uptake. The optimal cervical screening strategy is likely different for unvaccinated and vaccinated cohorts upon national HPV immunization. However, health authorities typically only provide a one-size-fits-all recommendation for the general population. We aimed to evaluate the cost-effectiveness for determining the optimal screening strategies for vaccinated and unvaccinated cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We considered the women population in Hong Kong which has a unique HPV infection and cervical cancer epidemiology compared to other regions in China and Asia. We used mathematical models which comprise a deterministic age-structured compartmental dynamic component and a stochastic individual-based cohort component to evaluate the cost-effectiveness of screening strategies for cervical screening. Following the recommendations in local guidelines in Hong Kong, we considered strategies that involved cytology, HPV testing, or co-testing as primary cervical screening. We also explored the impacts of adopting alternative de-intensified strategies for vaccinated cohorts. The 3-year cytology screening was used as the base comparator while no screening was also considered for vaccinated cohorts. Women\u2019s lifetime life years, quality-adjusted life years, and costs of screening and treatment were estimated from the societal perspective based on the year 2022 and were discounted by 3% annually. Incremental cost-effectiveness ratios (ICERs) were compared to a willingness to pay (WTP) threshold of one gross domestic product per capita (US $47,792). Probabilistic and one-way sensitivity analyses were conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among unvaccinated cohorts, the strategy that adds reflex HPV to triage mild cytology abnormality generated more life years saved than cytology-only screening and could be a cost-effective alternative. Among vaccinated cohorts, when vaccine uptake was 85% (based on the uptake in 2022), all guideline-based strategies (including the cytology-only screening) had ICERs above the WTP threshold when compared with no screening if the vaccine-induced protection duration was 20 years or longer. Under the same conditions, HPV testing with genotyping triage had ICERs (compared with no screening) below the WTP threshold if the routine screening interval was lengthened to 10 and 15 years or screening was initiated at ages 30 and 35 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HPV testing is a cost-effective alternative to cytology for vaccinated cohorts, and the associated optimal screening frequency depends on vaccine uptake. Health authorities should optimize screening recommendations by accounting for population vaccine uptake.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12916-023-02748-3","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T15:04:34Z","timestamp":1676041474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Maximizing the cost-effectiveness of cervical screening in the context of routine HPV vaccination by optimizing screening strategies with respect to vaccine uptake: a modeling analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Horace C. W.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K. L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"2748_CR1","unstructured":"International Agency for Research on Cancer (IARC), World Health Organization. Global cancer observatory. https:\/\/gco.iarc.fr\/."},{"key":"2748_CR2","unstructured":"World Health Organization. Cervical cancer elimination initiative. https:\/\/www.who.int\/initiatives\/cervical-cancer-elimination-initiative."},{"issue":"8","key":"2748_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1405044","volume":"372","author":"EA Joura","year":"2015","unstructured":"Joura EA, Giuliano AR, Iversen O-E, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711\u201323.","journal-title":"N Engl J Med"},{"key":"2748_CR4","doi-asserted-by":"publisher","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","volume":"144","author":"L Bruni","year":"2021","unstructured":"Bruni L, Saura-Lazaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010-2019. Prev Med. 2021;144:106399.","journal-title":"Prev Med"},{"issue":"2","key":"2748_CR5","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1016\/S2468-2667(17)30007-5","volume":"2","author":"JB Lew","year":"2017","unstructured":"Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2(2):e96\u2013e107.","journal-title":"Lancet Public Health"},{"issue":"4","key":"2748_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1136\/ijgc-2018-000161","volume":"29","author":"I Bains","year":"2019","unstructured":"Bains I, Choi YH, Soldan K, Jit M. Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. Int J Gynecol Cancer. 2019;29(4):669\u201375.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"2748_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/ijc.33207","volume":"148","author":"F Inturrisi","year":"2021","unstructured":"Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer C, et al. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 2021;148(2):320\u20138.","journal-title":"Int J Cancer"},{"key":"2748_CR8","doi-asserted-by":"crossref","unstructured":"Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst.\u00a02017;109(2):djw216.\u00a0https:\/\/academic.oup.com\/jnci\/article\/109\/2\/djw216\/2905864.","DOI":"10.1093\/jnci\/djw216"},{"issue":"4","key":"2748_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/ijc.31094","volume":"142","author":"R Landy","year":"2018","unstructured":"Landy R, Windridge P, Gillman MS, Sasieni PD. What cervical screening is appropriate for women who have been vaccinated against high risk HPV? A simulation study. Int J Cancer. 2018;142(4):709\u201318.","journal-title":"Int J Cancer"},{"key":"2748_CR10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejca.2017.12.018","volume":"91","author":"K Pedersen","year":"2018","unstructured":"Pedersen K, Burger EA, Nygard M, Kristiansen IS, Kim JJ. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68\u201375.","journal-title":"Eur J Cancer"},{"issue":"12","key":"2748_CR11","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1002\/ijc.30392","volume":"139","author":"KT Simms","year":"2016","unstructured":"Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer. 2016;139(12):2771\u201380.","journal-title":"Int J Cancer"},{"issue":"3","key":"2748_CR12","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.3802\/jgo.2020.31.e55","volume":"31","author":"ES Aoki","year":"2020","unstructured":"Aoki ES, Yin R, Li K, Bhatla N, Singhal S, Ocviyanti D, et al. National screening programs for cervical cancer in Asian countries. J Gynecol Oncol. 2020;31(3):e55.","journal-title":"J Gynecol Oncol"},{"key":"2748_CR13","volume-title":"Nation plans to launch free HPV vaccinations","author":"National Health Commission of the People\u2019s Republic of China","year":"2022","unstructured":"National Health Commission of the People\u2019s Republic of China. Nation plans to launch free HPV vaccinations; 2022."},{"key":"2748_CR14","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/jmv.21575","volume":"81","author":"PKS Chan","year":"2009","unstructured":"Chan PKS, Ho WCS, Wong MCS, Chang AR, Chor JSY, Yu M-Y. Epidemiologic risk profile of infection with different groups of human papillomaviruses. J Med Virol. 2009;81:1635\u201344.","journal-title":"J Med Virol"},{"issue":"5","key":"2748_CR15","doi-asserted-by":"publisher","first-page":"e19244","DOI":"10.1371\/journal.pone.0019244","volume":"6","author":"SS Liu","year":"2011","unstructured":"Liu SS, Chan KYK, Leung RCY, Chan KKL, Tam KF, Luk MHM, et al. Prevalence and risk factors of human papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One. 2011;6(5):e19244.","journal-title":"PLoS One"},{"key":"2748_CR16","volume-title":"ICO\/IARC Information Centre on HPV and Cervical Cancer (HPV Information Centre)","author":"L Bruni","year":"2021","unstructured":"Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gomez D, et al. Human papillomavirus and related diseases in China. Summary Report 22 October 2021. In: ICO\/IARC Information Centre on HPV and Cervical Cancer (HPV Information Centre); 2021."},{"key":"2748_CR17","unstructured":"Hong Kong Cancer Registry. http:\/\/www3.ha.org.hk\/cancereg\/."},{"key":"2748_CR18","unstructured":"Cervical Screening Programme, Department of Health. https:\/\/www.cervicalscreening.gov.hk\/en\/index.html."},{"key":"2748_CR19","volume-title":"The Hong Kong College of obstetricians and gynaecologists","author":"The Hong Kong College of Obstetricians and Gynaecologists","year":"2016","unstructured":"The Hong Kong College of Obstetricians and Gynaecologists. Guidelines for cervical cancer prevention and screening. In: The Hong Kong College of obstetricians and gynaecologists; 2016."},{"key":"2748_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12916-018-1118-3","volume":"16","author":"HCW Choi","year":"2018","unstructured":"Choi HCW, Jit M, Leung GM, Tsui K-L, Wu JT. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis. BMC Med. 2018;16:127.","journal-title":"BMC Med"},{"issue":"8","key":"2748_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMsa0707052","volume":"259","author":"JJ Kim","year":"2008","unstructured":"Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;259(8):821\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"2748_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jval.2017.11.010","volume":"21","author":"N Silva-Illanes","year":"2018","unstructured":"Silva-Illanes N, Espinoza M. Critical analysis of Markov models used for the economic evaluation of colorectal cancer screening: a systematic review. Value Health. 2018;21(7):858\u201373.","journal-title":"Value Health"},{"issue":"8","key":"2748_CR23","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/bjc.2013.471","volume":"109","author":"KH Tan","year":"2013","unstructured":"Tan KH, Simonella L, Wee HL, Roellin A, Lim YW, Lim WY, et al. Quantifying the natural history of breast cancer. Br J Cancer. 2013;109(8):2035\u201343.","journal-title":"Br J Cancer"},{"issue":"24","key":"2748_CR24","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1016\/j.vaccine.2009.09.125","volume":"28","author":"YH Choi","year":"2010","unstructured":"Choi YH, Jit M, Gay N, Cox A, Garnett GP, Edmunds WJ. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine. 2010;28(24):4091\u2013102.","journal-title":"Vaccine"},{"issue":"1","key":"2748_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28\u201341.","journal-title":"Emerg Infect Dis"},{"key":"2748_CR26","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/ijc.11334","volume":"106","author":"SJ Goldie","year":"2003","unstructured":"Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein MC, Franco EL. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16\/18 vaccine. Int J Cancer. 2003;106:896\u2013904.","journal-title":"Int J Cancer"},{"issue":"7","key":"2748_CR27","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1371\/journal.pmed.0020174","volume":"2","author":"HJ Wearing","year":"2005","unstructured":"Wearing HJ, Rohani P, Keeling MJ. Appropriate models for the management of infectious diseases. PLoS Med. 2005;2(7):e174.","journal-title":"PLoS Med"},{"issue":"9590","key":"2748_CR28","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890\u2013907.","journal-title":"Lancet"},{"issue":"12","key":"2748_CR29","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1086\/588140","volume":"197","author":"OP Gunther","year":"2008","unstructured":"Gunther OP, Ogilvie G, Naus M, Young E, Patrick DM, Dobson S, et al. Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity? J Infect Dis. 2008;197(12):1653\u201361.","journal-title":"J Infect Dis"},{"issue":"2","key":"2748_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hkjn.2015.09.140","volume":"17","author":"FY Cheung","year":"2011","unstructured":"Cheung FY, Mang OWK, Law SCK. A population-based analysis of incidence, mortality, and stage-specific survival of cervical cancer patients in Hong Kong: 1997-2006. Hong Kong Med J. 2011;17(2):89\u201395.","journal-title":"Hong Kong Med J"},{"issue":"15","key":"2748_CR31","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/jnci\/djp183","volume":"101","author":"IMCM de Kok","year":"2009","unstructured":"de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst. 2009;101(15):1083\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"2748_CR32","doi-asserted-by":"publisher","first-page":"e49614","DOI":"10.1371\/journal.pone.0049614","volume":"7","author":"HC Johnson","year":"2012","unstructured":"Johnson HC, Elfstrom KM, Edmunds WJ. Inference of type-specific HPV transmissibility, progression and clearance rates: a mathematical modelling approach. PLoS One. 2012;7(11):e49614.","journal-title":"PLoS One"},{"key":"2748_CR33","unstructured":"Census and Statistics Department. http:\/\/www.censtatd.gov.hk\/home\/index.jsp."},{"issue":"5","key":"2748_CR34","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","volume":"3","author":"RV Barnabas","year":"2006","unstructured":"Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med. 2006;3(5):e138.","journal-title":"PLoS Med"},{"issue":"11","key":"2748_CR35","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/sim.5590","volume":"32","author":"IA Korostil","year":"2013","unstructured":"Korostil IA, Peters GW, Cornebise J, Regan DG. Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus. Stat Med. 2013;32(11):1917\u201353.","journal-title":"Stat Med"},{"issue":"49","key":"2748_CR36","doi-asserted-by":"publisher","first-page":"17408","DOI":"10.1073\/pnas.1408184111","volume":"111","author":"B Calderhead","year":"2014","unstructured":"Calderhead B. A general construction for parallelizing Metropolis-Hastings algorithms. Proc Natl Acad Sci U S A. 2014;111(49):17408\u201313.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2748_CR37","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1002\/ijc.24495","volume":"125","author":"PKS Chan","year":"2009","unstructured":"Chan PKS, Ho WCS, Yu M-Y, Pong W-M, Chan ACL, Chan AKC, et al. Distribution of human papillomavirus types in cervical cancers in Hong Kong: current situation and changes over the last decades. Int J Cancer. 2009;125(7):1671\u20137.","journal-title":"Int J Cancer"},{"issue":"2","key":"2748_CR38","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/1055-9965.EPI-10-0791","volume":"20","author":"RP Insinga","year":"2011","unstructured":"Insinga RP, Perez G, Wheeler CM, Koutsky LA, Garland SM, Leodolter S, et al. Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance. Cancer Epidemiol Biomark Prev. 2011;20(2):287\u201396.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2748_CR39","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/AOG.0b013e3181fe777f","volume":"116","author":"A-B Moscicki","year":"2010","unstructured":"Moscicki A-B, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116:1373\u201380.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2748_CR40","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/0272989X13493143","volume":"35","author":"C Jackson","year":"2015","unstructured":"Jackson C, Jit M, Sharples L, DeAngelis D. Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial. Med Decis Mak. 2015;35(2):148\u201361.","journal-title":"Med Decis Mak"},{"issue":"4","key":"2748_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1177\/0272989X10384738","volume":"31","author":"S Whyte","year":"2011","unstructured":"Whyte S, Walsh C, Chilcott J. Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Mak. 2011;31(4):625\u201341.","journal-title":"Med Decis Mak"},{"key":"2748_CR42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/oso\/9780198522669.003.0010","volume-title":"Bayesian statistics","author":"J Geweke","year":"1992","unstructured":"Geweke J. Evaluating the accuracy of sampling-based approaches to the calculation of posterior moments. In: Bernardo JM, Berger JO, Dawid AP, AFM S, editors. Bayesian statistics, vol. Volume 4. Oxford: Oxford University Press; 1992. p. 169\u201393."},{"key":"2748_CR43","volume-title":"LCQ10: human papillomavirus vaccination programme","author":"Legislative Council","year":"2021","unstructured":"Legislative Council. LCQ10: human papillomavirus vaccination programme; 2021."},{"issue":"12","key":"2748_CR44","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(20)30524-6","volume":"21","author":"C Porras","year":"2020","unstructured":"Porras C, Tsang SH, Herrero R, Guillen D, Darragh TM, Stoler MH, et al. Efficacy of the bivalent HPV vaccine against HPV 16\/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020;21(12):1643\u201352.","journal-title":"Lancet Oncol"},{"key":"2748_CR45","doi-asserted-by":"publisher","first-page":"100401","DOI":"10.1016\/j.eclinm.2020.100401","volume":"23","author":"SK Kjaer","year":"2020","unstructured":"Kjaer SK, Nygard M, Sundstrom K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020;23:100401.","journal-title":"EClinicalMedicine"},{"issue":"10","key":"2748_CR46","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malagon","year":"2012","unstructured":"Malagon T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781\u20139.","journal-title":"Lancet Infect Dis"},{"key":"2748_CR47","volume-title":"Edited by Department of Health","author":"Centre for Health Protection, Department of Health","year":"2020","unstructured":"Centre for Health Protection, Department of Health. About human papillomavirus (HPV) vaccination. In: Edited by Department of Health: Hong Kong Special Administrative Region; 2020."},{"key":"2748_CR48","volume-title":"LCQ18: assisting women in preventing gynaecological diseases","author":"Legislative Council","year":"2022","unstructured":"Legislative Council. LCQ18: assisting women in preventing gynaecological diseases; 2022."},{"issue":"1","key":"2748_CR49","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.vaccine.2013.10.068","volume":"32","author":"HCW Choi","year":"2013","unstructured":"Choi HCW, Leung GM, Woo PPS, Jit M, Wu JT. Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: a survey of mothers and adolescents. Vaccine. 2013;32(1):78\u201384.","journal-title":"Vaccine"},{"key":"2748_CR50","volume-title":"Youth Sexuality Study","author":"The Family Planning Association of Hong Kong","year":"2016","unstructured":"The Family Planning Association of Hong Kong. Youth Sexuality Study. 2016. https:\/\/www.famplan.org.hk\/en\/media-centre\/press-releases\/detail\/fpahk-report-on-youth-sexuality-study."},{"key":"2748_CR51","volume-title":"Recommendations on prevention and screening for cervical cancer","author":"Cancer Expert Working Group on Cancer Prevention and Screening, Centre for Health Protection","year":"2021","unstructured":"Cancer Expert Working Group on Cancer Prevention and Screening, Centre for Health Protection. Recommendations on prevention and screening for cervical cancer; 2021."},{"issue":"Suppl 3","key":"2748_CR52","first-page":"S20","volume":"17","author":"JT Wu","year":"2011","unstructured":"Wu JT. Cervical cancer prevention through cytologic and human papillomavirus DNA screening in Hong Kong Chinese women. Hong Kong Med J. 2011;17(Suppl 3):S20\u20134.","journal-title":"Hong Kong Med J"},{"key":"2748_CR53","unstructured":"Cervical Screening Programme, Department of Health. Cervical cancer screening coverage. http:\/\/www.cervicalscreening.gov.hk\/english\/sr\/sr_statistics_ccsc.html."},{"issue":"6","key":"2748_CR54","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/01.mlr.0000128007.04494.29","volume":"42","author":"P Adab","year":"2004","unstructured":"Adab P, McGhee SM, Yanova J, Wong CM, Hedley AJ. Effectiveness and efficiency of opportunistic cervical cancer screening: comparison with organized screening. Med Care. 2004;42(6):600\u20139.","journal-title":"Med Care"},{"key":"2748_CR55","volume-title":"Thematic household survey report - report no.12","author":"Census and Statistics Department","year":"2003","unstructured":"Census and Statistics Department. Thematic household survey report - report no.12; 2003."},{"key":"2748_CR56","unstructured":"eHealth. Electronic Health Record Sharing System (eHRSS). https:\/\/www.ehealth.gov.hk\/en\/index.html."},{"issue":"9","key":"2748_CR57","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/cncy.21297","volume":"121","author":"Q-J Pan","year":"2013","unstructured":"Pan Q-J, Hu S-y, Zhang X, Ci P-w, Zhang W-h, Guo H-q, et al. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China. Cancer Cytopathol. 2013;121(9):473\u201382.","journal-title":"Cancer Cytopathol"},{"key":"2748_CR58","unstructured":"CADTH. HPV testing for primary cervical cancer screening: a health technology assessment. CADTH Optimal Use Report. 2019, 7(1b). https:\/\/www.cadth.ca\/sites\/default\/files\/ou-tr\/op0530-hpv-testing-for-pccreport.pdf."},{"key":"2748_CR59","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ijc.21955","volume":"119","author":"J Cuzick","year":"2006","unstructured":"Cuzick J, Clavel C, Petry K-U, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119:1095\u2013101.","journal-title":"Int J Cancer"},{"issue":"1","key":"2748_CR60","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/ijc.21299","volume":"18","author":"PKS Chan","year":"2006","unstructured":"Chan PKS, Cheung TH, Tam AOY, Lo KWK, Yim SF, Yu MMY, et al. Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer. 2006;18(1):243\u20135.","journal-title":"Int J Cancer"},{"issue":"4","key":"2748_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3343\/alm.2014.34.4.279","volume":"34","author":"KS Park","year":"2014","unstructured":"Park KS, Kim J-Y, Ki C-S, Lee NY. Comparison of the Digene HPV genotyping LQ test and the PANArray HPV genotyping chip for detection of high-risk or probable high-risk human papillomavirus genotypes. Ann Lad Med. 2014;34(4):279\u201385.","journal-title":"Ann Lad Med"},{"key":"2748_CR62","volume-title":"Revisions to list of charges: Gazette No. 3884","author":"Hospital Authority","year":"2017","unstructured":"Hospital Authority. Revisions to list of charges: Gazette No. 3884: Hong Kong Special Administrative Region; 2017."},{"key":"2748_CR63","volume-title":"Hospital authority statistical report","author":"H Authority","year":"2020","unstructured":"Authority H. Hospital authority statistical report; 2020."},{"issue":"1","key":"2748_CR64","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13643-022-02017-z","volume":"11","author":"T Sefuthi","year":"2022","unstructured":"Sefuthi T, Nkonki L. A systematic review of economic evaluations of cervical cancer screening methods. Syst Rev. 2022;11(1):162.","journal-title":"Syst Rev"},{"key":"2748_CR65","unstructured":"Census and Statistics Department. https:\/\/www.censtatd.gov.hk\/home\/index.jsp."},{"issue":"6","key":"2748_CR66","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1200\/JCO.2006.06.0210","volume":"25","author":"PPS Woo","year":"2007","unstructured":"Woo PPS, Kim JJ, Leung GM. What is the most cost-effective population-based cancer screening program for Chinese woman? J Clin Oncol. 2007;25(6):617\u201324.","journal-title":"J Clin Oncol"},{"key":"2748_CR67","unstructured":"Census and Statistics Department. Women and men in Hong Kong - key statistics;\u00a02021."},{"key":"2748_CR68","unstructured":"Myers ER, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analog scales vs time trade-off elicitation. In: 21st International Papillomavirus Conference and Clinical Workshop: 2004. Mexico City; 2004."},{"key":"2748_CR69","volume-title":"Hong Kong Special Administrative Region","author":"Hospital Authority","year":"2017","unstructured":"Hospital Authority. Revisions to list of charges: G.N. 3884. In: Hong Kong Special Administrative Region; 2017."},{"key":"2748_CR70","volume-title":"Legislative Council Panel on Health Services - review of fees and charges for non-eligible persons and private patients in the Hospital Authority (LC Paper No. CB (2)331\/12-13(03))","author":"Legislative Council","year":"2012","unstructured":"Legislative Council. Legislative Council Panel on Health Services - review of fees and charges for non-eligible persons and private patients in the Hospital Authority (LC Paper No. CB (2)331\/12-13(03)). 2012."},{"key":"2748_CR71","unstructured":"Hospital Authority. Fees and charges. http:\/\/www.ha.org.hk\/visitor\/ha_visitor_index.asp?Content_ID=10045&Lang=ENG."},{"issue":"1","key":"2748_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12962-021-00328-x","volume":"19","author":"TH Cheung","year":"2021","unstructured":"Cheung TH, Cheng SSY, Hsu DC, Wong QW, Pavelyev A, Walia A, et al. The impact and cost-effectiveness of 9-valent human papillomavirus vaccine in adolescent females in Hong Kong. Cost Eff Resour Alloc. 2021;19(1):75.","journal-title":"Cost Eff Resour Alloc"},{"issue":"6","key":"2748_CR73","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1365-2753.2011.01776.x","volume":"18","author":"CKH Wong","year":"2012","unstructured":"Wong CKH, Lam CLK, Poon JTC, McGhee SM, Law WL, Kwong DLW, et al. Direct medical costs of care for Chinese patients with colorectal neoplasia: a health care service provider perspective. J Eval Clin Pract. 2012;18(6):1203\u201310.","journal-title":"J Eval Clin Pract"},{"issue":"3","key":"2748_CR74","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1177\/0269216307079825","volume":"21","author":"DMW Tse","year":"2007","unstructured":"Tse DMW, Chan KS, Lam WM, Leu KS, Lam PT. The impact of palliative care on cancer deaths in Hong Kong: a retrospective study of 494 cancer deaths. Palliat Med. 2007;21(3):425\u201333.","journal-title":"Palliat Med"},{"issue":"2","key":"2748_CR75","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2468-2667(16)30019-6","volume":"1","author":"KT Simms","year":"2016","unstructured":"Simms KT, Laprise J-F, Smith MA, Lew J-B, Caruana M, Brisson M, et al. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health. 2016;1(2):e66\u201375.","journal-title":"Lancet Public Health"},{"key":"2748_CR76","unstructured":"Census and Statistics Department. National accounts. https:\/\/www.censtatd.gov.hk\/en\/scode250.html."},{"issue":"12","key":"2748_CR77","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer TT-T, Hutubessy R, Kieny M-P, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Organ. 2016;94(12):925\u201330.","journal-title":"Bull World Health Organ"},{"issue":"6, Suppl 7","key":"2748_CR78","first-page":"S13","volume":"20","author":"IOL Wong","year":"2014","unstructured":"Wong IOL, Schooling CM, Cowling BJ. Cost-effectiveness of Helicobacter pylori screening and treatment for gastric cancer in Hong Kong: a decision analytic approach. Hong Kong Med J. 2014;20(6, Suppl 7):S13\u20135.","journal-title":"Hong Kong Med J"},{"issue":"Suppl 6","key":"2748_CR79","first-page":"4","volume":"21","author":"CL Lam","year":"2015","unstructured":"Lam CL, Law WL, Poon JT, Chan P, Wong CK, McGhee SM, et al. Health-related quality of life in patients with colorectal neoplasm and cost-effectiveness of colorectal cancer screening in Hong Kong. Hong Kong Med J. 2015;21(Suppl 6):4\u20138.","journal-title":"Hong Kong Med J"},{"key":"2748_CR80","doi-asserted-by":"publisher","first-page":"651299","DOI":"10.3389\/fonc.2021.651299","volume":"11","author":"SF Lee","year":"2021","unstructured":"Lee SF, Choi HCW, Chan SK, Lam KO, Lee VHF, Wong IOL, et al. Cost-effectiveness of anti-epidermal growth factor receptor therapy versus bevacizumab in KRAS wild-type (WT), pan-RAS WT, and pan-RAS WT left-sided metastatic colorectal cancer. Front Oncol. 2021;11:651299.","journal-title":"Front Oncol"},{"issue":"3","key":"2748_CR81","doi-asserted-by":"publisher","first-page":"e0247860","DOI":"10.1371\/journal.pone.0247860","volume":"16","author":"JHS You","year":"2021","unstructured":"You JHS, Cho WCS, Ming WK, Li YC, Kwan CK, Au KH, et al. EGFR mutation-guided use of afatinib, erlotinib and gefitinib for advanced non-small-cell lung cancer in Hong Kong - a cost-effectiveness analysis. PLoS One. 2021;16(3):e0247860.","journal-title":"PLoS One"},{"issue":"2","key":"2748_CR82","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","volume":"56","author":"N Demarteau","year":"2011","unstructured":"Demarteau N, Detournay B, Tehard B, Hasnaoui AE, Standaert B. A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. Int J Public Health. 2011;56(2):153\u201362.","journal-title":"Int J Public Health"},{"key":"2748_CR83","doi-asserted-by":"publisher","first-page":"a769","DOI":"10.1136\/bmj.a769","volume":"337","author":"M Jit","year":"2008","unstructured":"Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. Br Med J. 2008;337:a769.","journal-title":"Br Med J"},{"issue":"9769","key":"2748_CR84","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0140-6736(10)62342-2","volume":"377","author":"AR Giuliano","year":"2011","unstructured":"Giuliano AR, Lee J-H, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932\u201340.","journal-title":"Lancet"},{"issue":"3","key":"2748_CR85","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1158\/1055-9965.EPI-08-1012","volume":"18","author":"H Trottier","year":"2009","unstructured":"Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, et al. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Cancer Epidemiol Biomark Prev. 2009;18(3):854\u201362.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"9","key":"2748_CR86","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","volume":"213","author":"DC Beachler","year":"2016","unstructured":"Beachler DC, Jenkins G, Safaeian M, Kreimer AR, Wentzensen N. Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis. J Infect Dis. 2016;213(9):1444\u201354.","journal-title":"J Infect Dis"},{"issue":"2","key":"2748_CR87","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000493737","volume":"63","author":"L Sichero","year":"2019","unstructured":"Sichero L, Giuliano AR, Villa LL. Human papillomavirus and genital disease in men: What we have learned from the HIM study. Acta Cytol. 2019;63(2):109\u201317.","journal-title":"Acta Cytol"},{"issue":"1","key":"2748_CR88","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12913-021-07460-7","volume":"22","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Serv Res. 2022;22(1):114.","journal-title":"BMC Health Serv Res"},{"key":"2748_CR89","doi-asserted-by":"publisher","first-page":"100184","DOI":"10.1016\/j.pvr.2019.100184","volume":"8","author":"K Canfell","year":"2019","unstructured":"Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, et al. HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Res. 2019;8:100184.","journal-title":"Papillomavirus Res"},{"key":"2748_CR90","unstructured":"Public Health England. Cervical screening: programme overview. https:\/\/www.gov.uk\/guidance\/cervical-screening-programme-overview."},{"key":"2748_CR91","unstructured":"Department of Health A. National Cervical Screening Program. https:\/\/www.health.gov.au\/initiatives-and-programs\/national-cervical-screening-program."},{"issue":"6","key":"2748_CR92","doi-asserted-by":"publisher","first-page":"e0198615","DOI":"10.1371\/journal.pone.0198615","volume":"13","author":"T Cheung","year":"2018","unstructured":"Cheung T, Lau JTF, Wang JZ, Mo PKH, Ho YS. Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among male baccalaureate students in Hong Kong. PLoS One. 2018;13(6):e0198615.","journal-title":"PLoS One"},{"issue":"10224","key":"2748_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","volume":"395","author":"M Brisson","year":"2020","unstructured":"Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, et al. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):575\u201390.","journal-title":"Lancet"},{"issue":"19","key":"2748_CR94","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.024","volume":"36","author":"SS Ng","year":"2018","unstructured":"Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529\u201344.","journal-title":"Vaccine"},{"issue":"47","key":"2748_CR95","first-page":"541","volume":"94","author":"World Health Organization","year":"2019","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019: conclusions and recommendations. Wkly Epidemiol Rec. 2019;94(47):541\u201360.","journal-title":"Wkly Epidemiol Rec"},{"issue":"24","key":"2748_CR96","first-page":"261","volume":"97","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2022: conclusions and recommendations. Wkly Epidemiol Rec. 2022;97(24):261\u201376.","journal-title":"Wkly Epidemiol Rec"},{"issue":"1","key":"2748_CR97","doi-asserted-by":"publisher","first-page":"e0145548","DOI":"10.1371\/journal.pone.0145548","volume":"11","author":"SK Naber","year":"2016","unstructured":"Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M. Cervical cancer screening in partly HPV vaccinated cohorts - a cost-effectiveness analysis. PLoS One. 2016;11(1):e0145548.","journal-title":"PLoS One"},{"key":"2748_CR98","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/591095","volume":"198","author":"AR Giuliano","year":"2008","unstructured":"Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee J-H, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis. 2008;198:827\u201335.","journal-title":"J Infect Dis"},{"issue":"11","key":"2748_CR99","first-page":"e119","volume":"5","author":"F Wei","year":"2016","unstructured":"Wei F, Yin K, Wu X, Lan J, Huang S, Sheng W, et al. Human papillomavirus prevalence and associated factors in women and men in south China: a population-based study. Emerg Microbes Infect. 2016;5(11):e119.","journal-title":"Emerg Microbes Infect"},{"issue":"7","key":"2748_CR100","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/infdis\/jix057","volume":"215","author":"JW Gargano","year":"2017","unstructured":"Gargano JW, Unger ER, Liu G, Steinau M, Meites E, Dunne E, et al. Prevalence of genital human papillomavirus in males, United States, 2013-2014. J Infect Dis. 2017;215(7):1070\u20139.","journal-title":"J Infect Dis"},{"issue":"14","key":"2748_CR101","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/sim.4780141404","volume":"14","author":"SW Duffy","year":"1995","unstructured":"Duffy SW, Chen HH, Tabar L, Day NE. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase. Stat Med. 1995;14(14):1531\u201343.","journal-title":"Stat Med"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02748-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-023-02748-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-023-02748-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,13]],"date-time":"2024-10-13T23:19:26Z","timestamp":1728861566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-023-02748-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1186\/s12916-023-02748-3","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"16 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}